Drug discovery for spinal muscular atrophy

Bibliography

• LEFEBVRE S, BURGLEN L, REBOULLET S et al.: Identification and characterization of a spinal muscular atrophy-determining gene. Cell (1995) 80(1):155-165.
   PubMed Web of Science ®Google Scholar
• PEARN J: Incidence, prevalence, and gene frequency studies of chronic childhood spinal muscular atrophy. J. Med. Genet. (1978) 15(6):409-413.
   PubMed Web of Science ®Google Scholar
• FELDKOTTER M, SCHWARZER V, WIRTH R, WIENKER TF, WIRTH B: Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy. Am. J. Hum. Genet. (2002) 70(2):358-368.
   PubMed Web of Science ®Google Scholar
• MUNSAT TL, DAVIES KE: International SMA consortium meeting. (26-28 June 1992, Bonn, Germany). Neuromuscul. Disord. (1992) 2(5-6):423-428.
   PubMed Web of Science ®Google Scholar
• RUDNIK-SCHÖNEBORN S, FORKERT R, HAHNEN E, WIRTH B, ZERRES K: Clinical spectrum and diagnostic criteria of infantile spinal muscular atrophy: further delineation on the basis of SMN gene deletion findings. Neuropediatrics (1996) 27(1):8-15.
   PubMed Web of Science ®Google Scholar
• WIRTH B, HERZ M, WETTER A et al.: Quantitative analysis of survival motor neuron copies: identification of subtle SMN1 mutations in patients with spinal muscular atrophy, genotype–phenotype correlation, and implications for genetic counseling. Am. J. Hum. Genet. (1999) 64(5):1340-1356.
   PubMed Web of Science ®Google Scholar
• OGINO S, WILSON RB: Importance of standard nomenclature for SMN1 small intragenic (‘subtle’) mutations. Hum. Mutat. (2004) 23(4):392-393.
   PubMed Web of Science ®Google Scholar
• WIRTH B: An update of the mutation spectrum of the survival motor neuron gene (SMN1) in autosomal recessive spinal muscular atrophy (SMA). Hum. Mutat. (2000) 15(3):228-237.
   PubMed Web of Science ®Google Scholar
• SUN Y, GRIMMLER M, SCHWARZER V, SCHOENEN F, FISCHER U, WIRTH B: Molecular and functional analysis of intragenic SMN1 mutations in patients with spinal muscular atrophy. Hum. Mutat. (2005) 25(1):64-71.
   PubMed Web of Science ®Google Scholar
• BURGLEN L, LEFEBVRE S, CLERMONT O et al.: Structure and organization of the human survival motor neurone (SMN) gene. Genomics (1996) 32(3):479-482.
   PubMed Web of Science ®Google Scholar
• BRAHE C: Copies of the survival motor neuron gene in spinal muscular atrophy: the more, the better. Neuromuscul. Disord. (2000) 10(4-5):274-275.
   PubMed Web of Science ®Google Scholar
• BURGHES AH: When is a deletion not a deletion? When it is converted. Am. J. Hum. Genet. (1997) 61(1):9-15.
   PubMed Web of Science ®Google Scholar
• HSIEH-LI HM, CHANG JG, JONG YJ et al.: A mouse model for spinal muscular atrophy. Nat. Genet. (2000) 24(1):66-70.
   PubMed Web of Science ®Google Scholar
• MONANI UR, SENDTNER M, COOVERT DD et al.: The human centromeric survival motor neuron gene (SMN2) rescues embryonic lethality in Smn(-/-) mice and results in a mouse with spinal muscular atrophy. Hum. Mol. Genet. (2000) 9(3):333-339.
   PubMed Web of Science ®Google Scholar
• GENNARELLI M, LUCARELLI M, CAPON F et al.: Survival motor neuron gene transcript analysis in muscles from spinal muscular atrophy patients. Biochem. Biophys. Res. Commun. (1995) 213(1):342-348.
   PubMed Web of Science ®Google Scholar
• LORSON CL, HAHNEN E, ANDROPHY EJ, WIRTH B: A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc. Natl. Acad. Sci. USA (1999) 96(11):6307-6311.
   PubMed Web of Science ®Google Scholar
• LIM SR, HERTEL KJ: Modulation of survival motor neuron pre-mRNA splicing by inhibition of alternative 3′ splice site pairing. J. Biol. Chem. (2001) 276(48):45476-45483.
   PubMed Web of Science ®Google Scholar
• LORSON CL, ANDROPHY EJ: An exonic enhancer is required for inclusion of an essential exon in the SMA-determining gene SMN. Hum. Mol. Genet. (2000) 9(2):259-265.
   PubMed Web of Science ®Google Scholar
• CARTEGNI L, KRAINER AR: Disruption of an SF2/ASF-dependent exonic splicing enhancer in SMN2 causes spinal muscular atrophy in the absence of SMN1. Nat. Genet. (2002) 30(4):377-384.
   PubMed Web of Science ®Google Scholar
• KASHIMA T, MANLEY JL: A negative element in SMN2 exon 7 inhibits splicing in spinal muscular atrophy. Nat. Genet. (2003) 34(4):460-463.
   PubMed Web of Science ®Google Scholar
• CARTEGNI L, HASTINGS ML, CALARCO JA, DE STANCHINA E, KRAINER AR: Determinants of exon 7 splicing in the spinal muscular atrophy genes, SMN1 and SMN2. Am. J. Hum. Genet. (2006) 78(1):63-77.
   PubMed Web of Science ®Google Scholar
• SINGH NN, ANDROPHY EJ, SINGH RN: In vivo selection reveals combinatorial controls that define a critical exon in the spinal muscular atrophy genes. RNA (2004) 10(8):1291-305.
   PubMed Web of Science ®Google Scholar
• SINGH NN, ANDROPHY EJ, SINGH RN: An extended inhibitory context causes skipping of exon 7 of SMN2 in spinal muscular atrophy. Biochem. Biophys. Res. Commun. (2004) 315(2):381-388.
   PubMed Web of Science ®Google Scholar
• HOFMANN Y, LORSON CL, STAMM S, ANDROPHY EJ, WIRTH B: Htra2-β1 stimulates an exonic splicing enhancer and can restore full-length SMN expression to survival motor neuron 2 (SMN2). Proc. Natl. Acad. Sci. USA (2000) 97(17):9618-9623.
   PubMed Web of Science ®Google Scholar
• HOFMANN Y, WIRTH B: hnRNP-G promotes exon 7 inclusion of survival motor neuron (SMN) via direct interaction with Htra2-β1. Hum. Mol. Genet. (2002) 11(17):2037-2049.
   PubMed Web of Science ®Google Scholar
• YOUNG PJ, DIDONATO CJ, HU D et al.: SRp30c-dependent stimulation of survival motor neuron (SMN) exon 7 inclusion is facilitated by a direct interaction with hTra2β1. Hum. Mol. Genet. (2002) 11(5):577-587.
   PubMed Web of Science ®Google Scholar
• BRICHTA L, HOFMANN Y, HAHNEN E et al.: Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy. Hum. Mol. Genet. (2003) 12(19):2481-2489.
   PubMed Web of Science ®Google Scholar
• SINGH NN, SINGH RN, ANDROPHY EJ: Modulating role of RNA structure in alternative splicing of a critical exon in the spinal muscular atrophy genes. Nucleic Acids Res. (2006) Epub ahead of print.
   Google Scholar
• VAN DER STEEGE G, GROOTSCHOLTEN PM, VAN DER VLIES P et al.: PCR-based DNA test to confirm clinical diagnosis of autosomal recessive spinal muscular atrophy. Lancet (1995) 345:985-986.
   PubMed Web of Science ®Google Scholar
• SINGH NK, SINGH NN, ANDROPHY EJ, SINGH RN: Splicing of a critical exon of human survival motor neuron is regulated by a unique silencer element located in the last intron. Mol. Cell. Biol. (2006) 26(4):1333-1346.
   PubMed Web of Science ®Google Scholar
• DIDONATO CJ, LORSON CL, DE REPENTIGNY Y et al.: Regulation of murine survival motor neuron (Smn) protein levels by modifying Smn exon 7 splicing. Hum. Mol. Genet. (2001) 10(23):2727-2736.
   PubMed Web of Science ®Google Scholar
• HELMKEN C, HOFMANN Y, SCHOENEN F et al.: Evidence for a modifying pathway in SMA discordant families: reduced SMN level decreases the amount of its interacting partners and Htra2-β1. Hum. Genet. (2003) 114(1):11-21.
   PubMed Web of Science ®Google Scholar
• LEFEBVRE S, BURLET P, LIU Q et al.: Correlation between severity and SMN protein level in spinal muscular atrophy. Nat. Genet. (1997) 16(3):265-269.
   PubMed Web of Science ®Google Scholar
• COOVERT DD, LE TT, MCANDREW PE et al.: The survival motor neuron protein in spinal muscular atrophy. Hum. Mol. Genet. (1997) 6(8):1205-1214.
   PubMed Web of Science ®Google Scholar
• LIU Q, DREYFUSS G: A novel nuclear structure containing the survival of motor neurons protein. EMBO J. (1996) 15(14):3555-3565.
   PubMed Web of Science ®Google Scholar
• HUA Y, ZHOU J: Rpp20 interacts with SMN and is re-distributed into SMN granules in response to stress. Biochem. Biophys. Res. Commun. (2004) 314(1):268-276.
   PubMed Web of Science ®Google Scholar
• YOUNG PJ, JENSEN KT, BURGER LR, PINTEL DJ, LORSON CL: Minute virus of mice NS1 interacts with the SMN protein, and they colocalize in novel nuclear bodies induced by parvovirus infection. J. Virol. (2002) 76(8):3892-3904.
   PubMed Web of Science ®Google Scholar
• MEISTER G, EGGERT C, FISCHER U: SMN-mediated assembly of RNPs: a complex story. Trends Cell Biol. (2002) 12(10):472-478.
   PubMed Web of Science ®Google Scholar
• GUBITZ AK, FENG W, DREYFUSS G: The SMN complex. Exp. Cell Res. (2004) 296(1):51-56.
   PubMed Web of Science ®Google Scholar
• JABLONKA S, ROSSOLL W, SCHRANK B et al.: The role of SMN in spinal muscular atrophy. J. Neurol. (2000) 247(Suppl. 1):I37-I42.
   PubMed Web of Science ®Google Scholar
• WIRTH B, BRICHTA L, HAHNEN E: Spinal muscular atrophy and therapeutic prospects. Prog. Mol. Subcell. Biol. (2006) 44:109-132.
   PubMedGoogle Scholar
• WIRTH B, BRICHTA L, HAHNEN E: Spinal muscular atrophy: from gene to therapy. Semin. Pediatr. Neurol. (2006) 13(2):121-131.
   PubMedGoogle Scholar
• WAN L, BATTLE DJ, YONG J et al.: The survival of motor neurons protein determines the capacity for snRNP assembly: biochemical deficiency in spinal muscular atrophy. Mol. Cell. Biol. (2005) 25(13):5543-5551.
   PubMed Web of Science ®Google Scholar
• WINKLER C, EGGERT C, GRADL D et al.: Reduced U snRNP assembly causes motor axon degeneration in an animal model for spinal muscular atrophy. Genes Dev. (2005) 19(19):2320-2330.
   PubMed Web of Science ®Google Scholar
• MCWHORTER ML, MONANI UR, BURGHES AH, BEATTIE CE: Knockdown of the survival motor neuron (Smn) protein in zebrafish causes defects in motor axon outgrowth and pathfinding. J. Cell Biol. (2003) 162(5):919-931.
   PubMed Web of Science ®Google Scholar
• ZHANG HL, PAN F, HONG D, SHENOI S, SINGER RH, BASSELL GJ: Active transport of the survival motor neuron protein and the role of exon-7 in cytoplasmic localization. J. Neurosci. (2003) 23(16):6627-6637.
   PubMed Web of Science ®Google Scholar
• CARREL TL, MCWHORTER ML, WORKMAN E et al.: Survival motor neuron function in motor axons is independent of functions required for small nuclear ribonucleoprotein biogenesis. J. Neurosci. (2006) 26(43):11014-11022.
   PubMed Web of Science ®Google Scholar
• ZHANG H, XING L, ROSSOLL W, WICHTERLE H, SINGER RH, BASSELL GJ: Multiprotein complexes of the survival of motor neuron protein SMN with Gemins traffic to neuronal processes and growth cones of motor neurons. J. Neurosci. (2006) 26(33):8622-8632.
   PubMed Web of Science ®Google Scholar
• ROSSOLL W, JABLONKA S, ANDREASSI C et al.: SMN, the spinal muscular atrophy-determining gene product, modulates axon growth and localization of β-actin mRNA in growth cones of motoneurons. J. Cell Biol. (2003) 163(4):801-812.
   PubMed Web of Science ®Google Scholar
• ROSSOLL W, KRONING AK, OHNDORF UM, STEEGBORN C, JABLONKA S, SENDTNER M: Specific interaction of Smn, the spinal muscular atrophy determining gene product, with hnRNP-R and gry-rbp/hnRNP-Q: a role for Smn in RNA processing in motor axons? Hum. Mol. Genet. (2002) 11(1):93-105.
   PubMed Web of Science ®Google Scholar
• MOURELATOS Z, ABEL L, YONG J, KATAOKA N, DREYFUSS G: SMN interacts with a novel family of hnRNP and spliceosomal proteins. EMBO J. (2001) 20(19):5443-5452.
   PubMed Web of Science ®Google Scholar
• RUDNIK-SCHÖNEBORN S, ROHRIG D, MORGAN G, WIRTH B, ZERRES K: Autosomal recessive proximal spinal muscular atrophy in 101 sibs out of 48 families: clinical picture, influence of gender, and genetic implications. Am. J. Med. Genet. (1994) 51(1):70-76.
   PubMed Web of Science ®Google Scholar
• SWOBODA KJ, PRIOR TW, SCOTT CB et al.: Natural history of denervation in SMA: relation to age, SMN2 copy number, and function. Ann. Neurol. (2005) 57(5):704-712.
   PubMed Web of Science ®Google Scholar
• MARKS PA, RICHON VM, MILLER T, KELLY WK: Histone deacetylase inhibitors. Adv. Cancer Res. (2004) 91:137-168.
   PubMed Web of Science ®Google Scholar
• CHANG JG, HSIEH-LI HM, JONG YJ, WANG MW, TSAI CH, LI H: Treatment of spinal muscular atrophy by sodium butyrate. Proc. Natl. Acad. Sci. USA (2001) 98(17):9808-9813.
   PubMed Web of Science ®Google Scholar
• JOHANNESSEN CU, JOHANNESSEN SI: Valproate: past, present, and future. CNS Drug Rev. (2003) 9(2):199-216.
   PubMedGoogle Scholar
• PAPATHEODOROU G, KUTCHER SP, KATIC M et al.: The efficacy and safety of divalproex sodium in the treatment of acute mania in adolescents and young adults: an open clinical trial. J. Clin. Psychopharmacol. (1995) 15(2):110-116.
   PubMed Web of Science ®Google Scholar
• MATHEW NT, KAILASAM J, MEADORS L, CHERNYSCHEV O, GENTRY P: Intravenous valproate sodium (depacon) aborts migraine rapidly: a preliminary report. Headache (2000) 40(9):720-723.
   PubMed Web of Science ®Google Scholar
• LONERGAN ET, CAMERON M, LUXENBERG J: Valproic acid for agitation in dementia. Cochrane Database Syst. Rev. (2004) (2):CD003945.
   Google Scholar
• SUMNER CJ, HUYNH TN, MARKOWITZ JA et al.: Valproic acid increases SMN levels in spinal muscular atrophy patient cells. Ann. Neurol. (2003) 54(5):647-654.
   PubMed Web of Science ®Google Scholar
• KRAMER OH, ZHU P, OSTENDORFF HP et al.: The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2. EMBO J. (2003) 22(13):3411-3420.
   PubMed Web of Science ®Google Scholar
• HAHNEN E, EYUPOGLU IY, BRICHTA L et al.: In vitro and ex vivo evaluation of second-generation histone deacetylase inhibitors for the treatment of spinal muscular atrophy. J. Neurochem. (2006) 98(1):193-202.
   PubMed Web of Science ®Google Scholar
• TSAI LK, TSAI MS, LIN TB, HWU WL, LI H: Establishing a standardized therapeutic testing protocol for spinal muscular atrophy. Neurobiol. Dis. (2006) 24(2):286-295.
   PubMed Web of Science ®Google Scholar
• PAZIN MJ, KADONAGA JT: What’s up and down with histone deacetylation and transcription? Cell (1997) 89(3):325-328.
   PubMed Web of Science ®Google Scholar
• BRICHTA L, HOLKER I, HAUG K, KLOCKGETHER T, WIRTH B: In vivo activation of SMN in spinal muscular atrophy carriers and patients treated with valproate. Ann. Neurol. (2006) 59(6):970-975.
   PubMed Web of Science ®Google Scholar
• WEIHL CC, CONNOLLY AM, PESTRONK A: Valproate may improve strength and function in patients with Type III/IV spinal muscle atrophy. Neurology (2006) 67(3):500-501.
   PubMed Web of Science ®Google Scholar
• ANDREASSI C, ANGELOZZI C, TIZIANO FD et al.: Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophy. Eur. J. Hum. Genet. (2004) 12(1):59-65.
   PubMed Web of Science ®Google Scholar
• MERCURI E, BERTINI E, MESSINA S et al.: Pilot trial of phenylbutyrate in spinal muscular atrophy. Neuromuscul. Disord. (2004) 14(2):130-135.
   PubMed Web of Science ®Google Scholar
• BRAHE C, VITALI T, TIZIANO FD et al.: Phenylbutyrate increases SMN gene expression in spinal muscular atrophy patients. Eur. J. Hum. Genet. (2005) 13(2):256-259.
   PubMed Web of Science ®Google Scholar
• MORLEY M, MOLONY CM, WEBER TM et al.: Genetic analysis of genome-wide variation in human gene expression. Nature (2004) 430(7001):743-747.
   PubMed Web of Science ®Google Scholar
• MERCURI E, BERTINI E, MESSINA S et al.: Randomized, double-blind, placebo-controlled trial of phenylbutyrate in spinal muscular atrophy. Neurology (2007) 68(1):51-55.
   PubMed Web of Science ®Google Scholar
• RIESSLAND M, BRICHTA L, HAHNEN E, WIRTH B: The benzamide M344, a novel histone deacetylase inhibitor, significantly increases SMN2 RNA/protein levels in spinal muscular atrophy cells. Hum. Genet. (2006) 120(1):101-110.
   PubMed Web of Science ®Google Scholar
• MORCEAU F, CHENAIS B, GILLET R, JARDILLIER JC, JEANNESSON P, TRENTESAUX C: Transcriptional and posttranscriptional regulation of erythroid gene expression in anthracycline-induced differentiation of human erythroleukemic cells. Cell Growth Differ. (1996) 7(8):1023-1029.
   PubMedGoogle Scholar
• SEHESTED M, JENSEN PB: Mapping of DNA topoisomerase II poisons (etoposide, clerocidin) and catalytic inhibitors (aclarubicin, ICRF-187) to four distinct steps in the topoisomerase II catalytic cycle. Biochem. Pharmacol. (1996) 51(7):879-886.
   PubMed Web of Science ®Google Scholar
• ANDREASSI C, JARECKI J, ZHOU J et al.: Aclarubicin treatment restores SMN levels to cells derived from type I spinal muscular atrophy patients. Hum. Mol. Genet. (2001) 10(24):2841-2849.
   PubMed Web of Science ®Google Scholar
• SAKURAI H, FUGONO J, YASUI H: Pharmacokinetic study and trial for preparation of enteric-coated capsule containing insulinomimetic vanadyl compounds: implications for clinical use. Mini-Rev. Med. Chem. (2004) 4(1):41-48.
   PubMed Web of Science ®Google Scholar
• CHETA D, ORASANU G, NICOLAIE T et al.: The influence of sodium metavanadate on the process of diabetogenesis in BB rats. J. Cell. Mol. Med. (2003) 7(4):447-454.
   PubMed Web of Science ®Google Scholar
• GERLING N, CULMSEE C, KLUMPP S, KRIEGLSTEIN J: The tyrosine phosphatase inhibitor orthovanadate mimics NGF-induced neuroprotective signaling in rat hippocampal neurons. Neurochem. Int. (2004) 44(7):505-520.
   PubMed Web of Science ®Google Scholar
• LU X, MAYSINGER D, HAGG T: Tyrosine phosphatase inhibition enhances neurotrophin potency and rescues nigrostriatal neurons in adult rats. Exp. Neurol. (2002) 178(2):259-267.
   PubMed Web of Science ®Google Scholar
• ZHANG ML, LORSON CL, ANDROPHY EJ, ZHOU J: An in vivo reporter system for measuring increased inclusion of exon 7 in SMN2 mRNA: potential therapy of SMA. Gene Ther. (2001) 8(20):1532-1538.
   PubMed Web of Science ®Google Scholar
• GRZESCHIK SM, GANTA M, PRIOR TW, HEAVLIN WD, WANG CH: Hydroxyurea enhances SMN2 gene expression in spinal muscular atrophy cells. Ann. Neurol. (2005) 58(2):194-202.
   PubMed Web of Science ®Google Scholar
• BARON-DELAGE S, ABADIE A, ECHANIZ-LAGUNA A, MELKI J, BERETTA L: Interferons and IRF-1 induce expression of the survival motor neuron (SMN) genes. Mol. Med. (2000) 6(11):957-968.
   PubMed Web of Science ®Google Scholar
• KINALI M, MERCURI E, MAIN M et al.: Pilot trial of albuterol in spinal muscular atrophy. Neurology (2002) 59(4):609-610.
   PubMed Web of Science ®Google Scholar
• ANGELOZZI C, TIZIANO FD, FIORI S et al.: Salbutamol increases SMN expression in SMN cell cultures: a rationale for further clinical studies. Report of the International SMA Meeting (2006):38 (Abstract).
   Google Scholar
• JARECKI J, CHEN X, BERNARDINO A et al.: Diverse small-molecule modulators of SMN expression found by high-throughput compound screening: early leads towards a therapeutic for spinal muscular atrophy. Hum. Mol. Genet. (2005) 14(14):2003-2018.
   PubMed Web of Science ®Google Scholar
• LORSON CL, STRASSWIMMER J, YAO JM et al.: SMN oligomerization defect correlates with spinal muscular atrophy severity. Nat. Genet. (1998) 19(1):63-66.
   PubMed Web of Science ®Google Scholar
• PAUSHKIN S, GUBITZ AK, MASSENET S, DREYFUSS G: The SMN complex, an assemblyosome of ribonucleoproteins. Curr. Opin. Cell Biol. (2002) 14(3):305-312.
   PubMed Web of Science ®Google Scholar
• SOSSI V, GIULI A, VITALI T et al.: Premature termination mutations in exon 3 of the SMN1 gene are associated with exon skipping and a relatively mild SMA phenotype. Eur. J. Hum. Genet. (2001) 9(2):113-120.
   PubMed Web of Science ®Google Scholar
• MATTIS VB, RAI R, WANG J, CHANG CW, COADY T, LORSON CL: Novel aminoglycosides increase SMN levels in spinal muscular atrophy fibroblasts. Hum. Genet. (2006) 120(4):589-601.
   PubMed Web of Science ®Google Scholar
• WOLSTENCROFT EC, MATTIS V, BAJER AA, YOUNG PJ, LORSON CL: A non-sequence-specific requirement for SMN protein activity: the role of aminoglycosides in inducing elevated SMN protein levels. Hum. Mol. Genet. (2005) 14(9):1199-210.
   PubMed Web of Science ®Google Scholar
• LUNN MR, ROOT DE, MARTINO AM et al.: Indoprofen upregulates the survival motor neuron protein through a cyclooxygenase-independent mechanism. Chem. Biol. (2004) 11(11):1489-1493.
   PubMed Web of Science ®Google Scholar
• CHANG HC, HUNG WC, CHUANG YJ, JONG YJ: Degradation of survival motor neuron (SMN) protein is mediated via the ubiquitin/proteasome pathway. Neurochem. Int. (2004) 45(7):1107-1112.
   PubMed Web of Science ®Google Scholar
• BAUGHAN T, SHABABI M, COADY TH, DICKSON AM, TULLIS GE, LORSON CL: Stimulating full-length SMN2 expression by delivering bifunctional RNAs via a viral vector. Mol. Ther. (2006) 14(1):54-62.
   PubMed Web of Science ®Google Scholar
• SKORDIS LA, DUNCKLEY MG, YUE B, EPERON IC, MUNTONI F: Bifunctional antisense oligonucleotides provide a trans-acting splicing enhancer that stimulates SMN2 gene expression in patient fibroblasts. Proc. Natl. Acad. Sci. USA (2003) 100(7):4114-4119.
   PubMed Web of Science ®Google Scholar
• CARTEGNI L, KRAINER AR: Correction of disease-associated exon skipping by synthetic exon-specific activators. Nat. Struct. Biol. (2003) 10(2):120-125.
   PubMedGoogle Scholar
• ALTER J, LOU F, RABINOWITZ A et al.: Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nat. Med. (2006) 12(2):175-177.
   PubMed Web of Science ®Google Scholar
• KILIC AC, CAPAN Y, VURAL I et al.: Preparation and characterization of PLGA nanospheres for the targeted delivery of NR2B-specific antisense oligonucleotides to the NMDA receptors in the brain. J. Microencapsul. (2005) 22(6):633-641.
   PubMed Web of Science ®Google Scholar
• EKESTERN E: Neurotrophic factors and amyotrophic lateral sclerosis. Neurodegener. Dis. (2004) 1(2-3):88-100.
   PubMed Web of Science ®Google Scholar
• LESBORDES JC, CIFUENTES-DIAZ C, MIROGLIO A et al.: Therapeutic benefits of cardiotrophin-1 gene transfer in a mouse model of spinal muscular atrophy. Hum. Mol. Genet. (2003) 12(11):1233-1239.
   PubMed Web of Science ®Google Scholar
• HADDAD H, CIFUENTES-DIAZ C, MIROGLIO A, ROBLOT N, JOSHI V, MELKI J: Riluzole attenuates spinal muscular atrophy disease progression in a mouse model. Muscle Nerve (2003) 28(4):432-437.
   PubMed Web of Science ®Google Scholar
• MERLINI L, SOLARI A, VITA G et al.: Role of gabapentin in spinal muscular atrophy: results of a multicenter, randomized Italian study. J. Child Neurol. (2003) 18(8):537-541.
   PubMed Web of Science ®Google Scholar
• MILLER RG, MOORE DH, DRONSKY V et al.: A placebo-controlled trial of gabapentin in spinal muscular atrophy. J. Neurol. Sci. (2001) 191(1-2):127-131.
   PubMed Web of Science ®Google Scholar
• DIDONATO CJ, PARKS RJ, KOTHARY R: Development of a gene therapy strategy for the restoration of survival motor neuron protein expression: implications for spinal muscular atrophy therapy. Hum. Gene Ther. (2003) 14(2):179-188.
   PubMed Web of Science ®Google Scholar
• AZZOUZ M, LE T, RALPH GS et al.: Lentivector-mediated SMN replacement in a mouse model of spinal muscular atrophy. J. Clin. Invest. (2004) 114(12):1726-1731.
   PubMed Web of Science ®Google Scholar
• HARPER JM, KRISHNAN C, DARMAN JS et al.: Axonal growth of embryonic stem cell-derived motoneurons in vitro and in motoneuron-injured adult rats. Proc. Natl. Acad. Sci. USA (2004) 101(18):7123-7128.
   PubMed Web of Science ®Google Scholar
• SALAH-MOHELLIBI N, MILLET G, ANDRE-SCHMUTZ I et al.: Bone marrow transplantation attenuates the myopathic phenotype of a muscular mouse model of spinal muscular atrophy. Stem Cells (2006) 24(12):2723-2732.
   PubMed Web of Science ®Google Scholar
• SUMNER CJ, KOLB SJ, HARMISON GG et al.: SMN mRNA and protein levels in peripheral blood: biomarkers for SMA clinical trials. Neurology (2006) 66(7):1067-1073.
   PubMed Web of Science ®Google Scholar
• LAI RY, PLAXCO KW, HEEGER AJ: Aptamer-based electrochemical detection of picomolar platelet-derived growth factor directly in blood serum. Anal. Chem. (2007) 79(1):229-233.
   PubMed Web of Science ®Google Scholar
• LEE JF, STOVALL GM, ELLINGTON AD: Aptamer therapeutics advance. Curr. Opin. Chem. Biol. (2006) 10(3):282-289.
   PubMed Web of Science ®Google Scholar
• ZERRES K, RUDNIK-SCHONEBORN S: Natural history in proximal spinal muscular atrophy. Clinical analysis of 445 patients and suggestions for a modification of existing classifications. Arch. Neurol. (1995) 52(5):518-523.
   PubMed Web of Science ®Google Scholar
• WIRTH B, BRICHTA L, SCHRANK B et al.: Mildly affected patients with spinal muscular atrophy are partially protected by an increased SMN2 copy number. Hum. Genet. (2006) 119(4):422-428.
   PubMed Web of Science ®Google Scholar
• YOUNG PJ, LE TT, DUNCKLEY M, NGUYEN TM, BURGHES AH, MORRIS GE: Nuclear gems and Cajal (coiled) bodies in fetal tissues: nucleolar distribution of the spinal muscular atrophy protein, SMN. Exp. Cell Res. (2001) 265(2):252-261.
   PubMed Web of Science ®Google Scholar